Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function Irinotecan is active against a variety of malignancies; ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results